Xenon Seven

Xenon Seven

Associate Director/Director, Commercial Data Management

Boston · Director

Sponsorship not specifiedDetected 20 hours ago
SnowflakeAWSAzureRESTMachine LearningData VisualizationProject ManagementSalesforceCRMVendor ManagementClinical TrialsPublic HealthPatient CareLeadershipCommunication

About the role

  • This position reports to the Senior Director, Data Strategy, Operations, Analytics & Reporting and will be based out of Boston, MA, USA in our Needham office.
  • We will consider remote locations for exceptional candidates.
  • The level of the position will be commensurate with the candidate's education and industry experience.

Responsibilities

  • Collaborate with internal and external partners on developing and operationalizing Xenon's commercial data ecosystem across pre-launch, launch, and post-launch phases
  • Manage and define how commercial data will be governed, documented, validated, accessed, escalated, and used across the organization
  • Serve as the primary commercial business partner managing Xenon's core data service partners (e.g. CDW, Data Aggregator, MDM, etc.) and data source partners, (e.g. Claims, Rx, SP, Payer, etc.) IT Partnership
  • Partner closely with IT on commercial data platform implementation, platform enhancements, system dependencies, integration patterns, security, compliance, performance, lineage, and architecture alignment
  • Establish and maintain data dictionaries, critical data elements, metadata, lineage, and business definitions for priority commercial master data domains
  • Design and manage a data stewardship process to ensure data quality issues are identified, communicated, prioritized, and resolved through consistent business-facing processes
  • Support development of a governed KPI/metrics catalog into report-ready data assets with accompanying data dictionaries

Requirements

  • Minimum undergraduate degree
  • 8+ years of relevant management experience or combination of degrees and experience
  • Experience supporting commercial data warehouse, data aggregation, MDM, data governance, data quality, reporting, or analytics initiatives
  • Strong understanding of HCP/HCO and payer master data, affiliation management, data stewardship, business definitions, data dictionaries, metadata, lineage, and data quality management
  • Ability to translate business needs into data requirements, business rules, vendor specifications, validation criteria, and operational processes
  • Experience partnering with IT, analytics, vendors, Legal, Compliance, Privacy, and business stakeholders.
  • Ability to operate in a lean, fast-paced, pre-launch or launch-stage biotech environment
  • Experience with tokenization/de-identification, claims/Rx data, SP/hub data, patient journey analytics, omnichannel engagement data, or field execution data
  • Minimum undergraduate degree; 8+ years of relevant management experience or combination of degrees and experience
  • Advanced degree in business, analytics, data management, information systems, life sciences, public health, or related field preferred
  • 5+ years of experience in pharmaceutical, biotech, life sciences, healthcare data operations, data management, data governance, or related roles
  • Experience working with most commercial data sources such as Rx, claims, CRM, HCP/HCO, payer, field activity, digital engagement, specialty pharmacy, hub/patient services, distribution, sales/inventory, formulary, or access data
  • Experience managing data vendors, data aggregators, MDM vendors, commercial data platforms, or analytics implementation partners
  • Strong project management, vendor management, communication, documentation, and cross-functional leadership skills
  • Experience supporting a first commercial launch or commercial data capability build in a small or mid-sized biotech
  • Experience with commercial data warehouse platforms, such as Snowflake, Azure, AWS, Boomi, Informatica, Veeva, Salesforce, IQVIA, Symphony, Komodo, MMIT, Definitive Healthcare, OneTrust, Power BI, Tableau, or related platforms/vendors

Compensation

  • Our Total Rewards program includes base salary, target bonus, and stock options, as well as a full range of benefits including medical, dental, vision, short-& long-term disability, accidental death & dismemberment, and life insurance progr

Company info

  • Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
  • What We Do:
  • We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026. Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial. In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting. We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
  • Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need.
  • We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
  • We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain.
  • Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications.
  • In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026.
  • Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication.
  • We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial.
  • In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting.
  • We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets.
  • Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
Apply directly at Xenon Seven →Create a free account for alerts like thisView Xenon Seven immigration profile

This listing is sourced directly from Xenon Seven's careers page and normalized into a canonical job model.